Vaccine Congress Washington Agenda

 

 

World Vaccine Congress Washington is a multi-faceted conference experience with over 300 industry leading speaker, 10 conferences, 8 workshops, 100+ exhibitors providing the most exciting vaccine event on the planet. It is carefully curated by an experienced team who are plugged into a global network. Our presenters are disruptors and visionary industry leaders from the biopharma industry. They are selected for their relevance, dynamism and insight. 

 

BOOK BY MAR 20 & SAVE

 

  

Washington D.C., 27 - 29 September 2020

Schedule

Create your personal agenda –check the favourite icon

Sep 2808:15
Conference pass
Sep 2808:45
Conference pass

Vaccinology for the 21st century in addressing emerging infectious diseases

Keynotes
Sep 2809:15
Conference pass

Deploying and implementing vaccines during an outbreak: EBOLA

Keynotes
  • Global strategy, alignment ad local partnerships between all stakeholders
  • Overcoming challenges in DRC for successful implementation and rapid response
  • Lessons learned with international deployment in outbreak regions
  • Applications to the current coronavirus outbreak
Paul Stoffels, Chief Scientific Officer, Johnson & Johnson
Kate O'Brien, Director, World Health Organisation
Jean-Jacques Muyembe-Tamfum, General Director, Democratic Republic of Congo
Sep 2811:20
Conference pass

INTERACTIVE ROUNDTABLES

Keynotes
Analytical Issues Impacting Quality in Vaccine Development
Best practices for site partnerships with CRO/PHARMA for vaccine trials
William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC
Changing scenario of veterinary vaccine market in the developing world
Choke points in vaccine study start up -- An investigator’s view
Correlates of protection – are they failing us or are we failing them?
Bruno Speder, Head Of Clinical Regulatory Affairs, SGS Life Sciences
De-Risking Vaccine Clinical Trials in Lower Resource Settings
Developing more effective vaccines for emerging/re-emerging pandemic threats
Dr James Cummings, President, ICON Government & Public Health Solutions
How to ensure your trial crosses the finish line - Trial design, operational roll-out, recruitment, retention and data collection
How to onboard new digital technologies for absolute quantification of AAV vectors as part of scalable purification process for gene therapies
How to tackle and prepare for global health challenges – focus on tackling AMR using vaccines
Immune Profiling - capturing the complexity of immune responses to vaccines and infections
Key Elements of building a successful partnership between sponsor and CRO
Karen Mccarthy, Executive Director, Vaccines, PPD
New qualitative analytical technology replacing antiquated plaque and TCID50 assays
Dr Gray Heppner, Chief Medical Officer And Managing Partner, Crozet BioPharma LLC
Sean Hart, Chief Executive Officer, LumaCyte
Pediatric vaccine trials – Recruitment and retention
Pros and cons of using animal models for evaluating HIV vaccines
The promise of nanovaccines and the question of safety
Dr Adel Talaat, Professor Of Microbiology, University of Wisconsin-Madison
Vaccine, Vaccination, and Immunization Law
Brian Abramson, Attorney and Treatise Author, Bloomberg Law
Sep 2814:10
Conference pass
Sep 2814:10
Conference pass

Firechat: How are our government agencies responding to public health emergencies?

Keynotes
  • What are the unique strengths of each agency?
  • Are we working collaboratively enough to effectively manage public health outbreaks and national security in a meaningful way?
  • Are there ways to improve synergistic vaccine research efforts?
  • The response strategy to current global outbreaks like corona
Moderator: Eric Lombardini, Director, US Army Medical Directorate of the Armed Forces Research Institute of Medical Sciences (USAMD-AFRIMS)
Sep 2814:30
Conference pass

AMR: What’s the strategy?

One Health
  • Insight on how the human health and veterinary medicine industry is contributing to the fight against AMR
Mahesh Kumar, Senior Vice President, Global Biologics Research, Zoetis
Jesse Sevcik, Director, Elanco Animal Health
Sep 2815:00
Conference pass

How can we be better prepared for vaccine launches? The future of the vaccine business from the executives

Keynotes
  • What are the greatest hurdles hat prevent a vaccine from making the final leap to patients?
  • Experiences from emerging infectious diseases and international settings
  • Considerations of an early engagement plan and ethics beyond vaccine development
Sanjay Gurunathan, VP Global Clinical Development, Sanofi Pasteur
Thomas Breuer, Senior Vice President, Chief Medical Officer, GSK Vaccines
Paul Stoffels, Chief Scientific Officer, Johnson & Johnson
William Gruber, Senior Vice President, Pfizer Vaccine Clinical Research, Pfizer
Sep 2815:20
Conference pass

The importance of a One Health approach to biodefense and biosecurity

One Health
  • Overview of current threats
  • Insight from US & European countries: How do our governments prepare for outbreaks?
  • How do we ensure rapid manufacturing capabilities for dealing with outbreaks?
Sep 2816:30
Conference pass

Global health challenges: Controlling treatable infectious diseases

Keynotes
  • Bridging multiple technologies for holistic treatment strategies
  • What have we learnt from HIV, TB, malaria, NTDs?
Ann Ginsberg, Deputy Director, TB Vaccines, The Bill & Melinda Gates Foundation
Thomas Breuer, Senior Vice President, Chief Medical Officer, GSK Vaccines
Daria Hazuda, Vice President, Therapeutic Area, Head Of Infectious Disease And Chief Scientific Officer, Merck Research Laboratories
Sep 2816:30
Conference pass
Sep 2816:30
Conference pass

Chair's opening remarks

Cancer & Immunotherapy
Sep 2816:30
Conference pass

Chair’s opening remarks

Clinical Development
Sep 2816:30
Conference pass
Sep 2816:35
Conference pass

Machine learning and biomarker discovery for understanding vaccine mode of action

Immune Profiling
Robert Van Den Berg, Director, GlaxoSmithKline Vaccines
Sep 2816:35
Conference pass

The importance of therapeutic cancer vaccination for EBV-positive malignancies

Cancer & Immunotherapy
  • EBV-positive cancers are richly infiltrated with diverse immune cells
  • Performing high dimensional phenotyping of EBV tumours
  • Exploring the antigen-specificity of infiltrating T-cells
  • How these results inform the development of therapeutic vaccine strategies
Sep 2816:35
Conference pass
Sep 2816:35
Conference pass

Manufacturing technology showcase: Development of a new manufacturing platform technology for human vaccines

Bioprocess & Manufacture
Sep 2816:35
Conference pass

Developing next-generation antibiotic alternatives for animals

Veterinary
Sep 2816:35
Conference pass

The Safety Platform for Emergency Vaccines (SPEAC) Project

Vaccine Safety
  • The Brighton Collaboration was created in 2000 with the goal of building trust in the safety of vaccines via rigorous science.
  • The Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration launched the Safety Platform for Emergency vACcines (SPEAC) Project on May 28, 2020.
  • SPEAC aims to support the emerging CEPI portfolio by creating practical solutions for harmonized safety assessment of CEPI vaccines by working:
    • To enhance vaccine safety assessment across CEPI development programs.
    • To harmonize vaccine safety monitoring during CEPI preclinical and clinical trials.
    • To provide a continuous improvement framework for the SPEAC program.
Sep 2816:35
Conference pass

Overcoming barriers to higher vaccination coverage using mobile technology

Supply & Logistics
Katriel Friedman, Chief Executive Officer, Charity Science Health
Sep 2816:40
Conference pass

Why is an HIV vaccine needed?

Clinical Development
  • Why is it taking so long to develop a vaccine
  • Update on current antiviral and bnAb pipeline
Sep 2816:55
Conference pass

Application of computational fluid dynamical modelling and process analytical technologies to complement traditional vaccine process development roadmaps

Bioprocess & Manufacture
Dr Stephen Craven, Functional Lead, APC
Sep 2817:00
Conference pass
Sep 2817:00
Conference pass

Targeting CMV for the development of effective GBM and MB immunotherapies

Cancer & Immunotherapy
Sep 2817:00
Conference pass

The impact of a universal influenza vaccine

Respiratory
Meagan Fitzpatrick, Assistant Professor Of The Center For Vaccine Development And Global Health, University of Maryland
Sep 2817:00
Conference pass

Norovirus vaccine development

Emerging and Infectious
Sep 2817:00
Conference pass

IgG-like antibodies as an alternative to antibiotics

Veterinary
Sep 2817:00
Conference pass

WHO Global Advisory Committee on Vaccine Safety – future challenges for worldwide vaccine safety

Vaccine Safety
Kate O'Brien, Director, World Health Organisation
Sep 2817:00
Conference pass

Data-driven last-mile health delivery systems

Supply & Logistics
Sep 2817:15
Conference pass

Development of a synthetic Shigella conjugate vaccine until early clinical development

Emerging and Infectious
Maarten Danial, Project Leader And Organic Chemist, Intravacc
Sep 2817:15
Conference pass

Next-generation vaccines and oncolytic viruses: Current challenges and future promise

Bioprocess & Manufacture
Practical solutions enabling rapid and sustainable production
Sep 2817:25
Conference pass

Using systems immunology to understand responses to vaccination

Immune Profiling
Amy Chung, Laboratory Head, Department of Microbiology and Immunology, The Peter Doherty Institute For Infection and Immunity
Sep 2817:25
Conference pass

Versamune plus a multi-epitopic mix of 6 different HPV16 E6 and E7 peptides designed to treat HPV-associated pre-cancers and cancers

Cancer & Immunotherapy
Sep 2817:25
Conference pass

Novel Recombinant Influenza Platform - C1 Gene Expression Platform / Speeding the Development, Lowering The Cost & Improving the Performance of Flu Vaccines

Respiratory
Sep 2817:25
Conference pass

Vaccines as alternatives to antibiotics for food producing animals

Veterinary
Sep 2817:25
Conference pass

Post-marketing safety considerations for a new vaccine developed exclusively for LMIC

Vaccine Safety
  • How to address post-marketing considerations in a region with diverse pharmacovigilance capabilities.
  • The interaction of national stakeholder and manufacturers to overcome challenges to collect safety information in post-marketing?
Sep 2817:30
Conference pass

Coordination and implementation needs for vaccines in developing and LMICs

Emerging and Infectious
Sep 2817:35
Conference pass

Manufacturing technology showcase: Scalable in vitro manufacturing of tailored vaccines

Bioprocess & Manufacture
Sep 2817:50
Conference pass

Longitudinal analysis of B cell transcripts provides insight into vaccine priming of broad responses against HIV and influenza virus

Immune Profiling
Sep 2817:50
Conference pass

DNA Vaccines to combat a broad range of viral associated cancers

Cancer & Immunotherapy
Sep 2817:50
Conference pass
Sep 2817:50
Conference pass

Reducing the use of antimicrobials through innovative universal subunit vaccine platform design

Veterinary
Sep 2817:50
Conference pass

The Ebola vaccine story; where are we now?

Vaccine Safety
  • Wrapping up the DRC outbreak
  • The licensure process and unique pathway to regulatory approval
  • Policy & ethical considerations
  • Innovations, challenges and lessons learned throughout development
  • Implications for development of future emerging /re-emerging disease vaccines
Sep 2817:50
Conference pass

Panel: How can industry work with vaccine non-profits to improve last mile delivery?

Supply & Logistics
  • What are the main challenges faced?
  • What should industry consider to better suit our needs?
    • Temperature stable vaccines, other considerations for products on the market
  • Case studies of what works / doesn’t work for current products
Sep 2817:55
Conference pass

Novel Methods for Synthesizing Self-Amplifying RNA Vaccines Improve Yields and Accelerate GMP Manufacturing

Bioprocess & Manufacture
Sep 2818:00
Conference pass

How to achieve elimination of cervical cancer through HPV vaccines by 2030

Keynotes
Kate O'Brien, Director, World Health Organisation
Sep 2818:00
Conference pass

Use of oral cholera vaccine as a key component to eliminate epidemic cholera as a public health threat

Emerging and Infectious
Sep 2818:00
Conference pass

Development of a CMV-based HIV vaccine in rhesus monkeys

Clinical Development
Sep 2818:15
Conference pass

Using bioinformatics tools to predict the immune response to a number of infectious diseases

Immune Profiling
Sep 2818:15
Conference pass

Late stage development of a novel DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV)

Cancer & Immunotherapy
Sep 2818:15
Conference pass

qPCR/sequencing assay development and validation in vaccine clinical studies/trials

Respiratory
Mark Wissel, Director of R&D, Viracor Eurofins BioPharma Services
Sep 2818:15
Conference pass

Non-neutralizing Ab and HIV vaccines, clinical and pre-clinical experience

Clinical Development
Sep 2818:15
Conference pass

Protein mimetics of HIV-1 broadly neutralizing Ab epitopes elicit virus-neutralizing sera in vivo

Bioprocess & Manufacture
  • Using an advanced reverse vaccinology approach for the development of vaccine inducing antibodies
Sep 2818:15
Conference pass

Protecting the immune system in poultry – role of vaccination

Veterinary
Sep 2818:15
Conference pass

Investing on late stage projects to contribute towards global health

Partnerships
Sep 2818:15
Conference pass

How can mobile laboratories improve safety and evaluation of vaccines during outbreaks?

Vaccine Safety
Trina Racine, Cordonnateur Scientifique, Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire De Quebec

Create your personal agenda –check the favourite icon

Sep 2909:00
Conference pass

Chair's opening remarks

Emerging and Infectious
David Weiner, Professor And Ww Smith Chair In Cancer Research Director Wistar Vaccine Center And Executive Vice President, The Wistar Institute
Sep 2909:00
Conference pass
Sep 2909:00
Conference pass
Sep 2909:00
Conference pass

Chair’s opening remarks

Partnerships
Hansilla Alaigh, Director, External Development, Emergent Biosolutions
Sep 2909:00
Conference pass
Sep 2909:10
Conference pass

RNA frameshift errors provide new product opportunities against cancer

Immune Profiling
Sep 2909:10
Conference pass

Update on approaches to the development of clinical combination therapies

Cancer & Immunotherapy
  • What are the fundamental principles of combination science?
  • Huge amounts of data have been generated from combination studies, how do you analyze these?
Sep 2909:10
Conference pass

Ph3 and beyond: Maternal RSV & older adult influenza vaccine programs

Respiratory
Gregory Glenn, President, Research And Development, Novavax
Sep 2909:10
Conference pass

COVID-19: A prototype pathogen demonstration project for pandemic preparedness

Emerging and Infectious
Barney Graham, Deputy Director Of Vaccine Research Center, National Institute of Health - NIAID
Sep 2909:10
Conference pass

Clinical trials of the future

Clinical Development
  • Use of real-world evidence for vaccine efficacy
  • How to get information from the field to a database
  • Regulatory perspective in new development areas
Moderator: William Gruber, Senior Vice President, Pfizer Vaccine Clinical Research, Pfizer
Todd Wilson, Director, Early Clinical Development, GSK Vaccines
Sep 2909:10
Conference pass

Panel: The Future of the Animal Health Business

Veterinary
  • Discussing the emerging trends in animal health & biologics (companion and production animals)
  • The emergence of human health technologies in the animal health space; Are these technologies too expensive to implement in animal health?
  • The importance of establishing strong collaboration/partnerships for advancing animal health innovation
  • What about emerging markets? - Finding success in Latin America, China & India etc.
Sep 2909:10
Conference pass

Panel: Mandatory vaccination policies around the world, are they working?

Vaccine Safety
  • What has been the impact of the introduction of mandatory vaccination and other policies globally?
    • Has it had a positive impact overall or has it worsened polarization?
  • What have been the most successful strategies for communication?
  • Medical and religious exemptions
  • What is the relationship between the forcefulness of a policy and its impact on the rate of vaccination?
  • Using big data to analyze the spread of misinformation?
Sep 2909:10
Conference pass

Overcoming challenges in clinical trial logistics and product planning for the introduction of new vaccines

Supply & Logistics
Sep 2909:40
Conference pass

Immune responses to malaria infection and immunization

Immune Profiling
Ken Stuart, Founder, Center For Infectious Disease Research
Sep 2909:40
Conference pass

Panel: Targeted approaches to combinations, what’s working?

Cancer & Immunotherapy
  • What strategies can we use to identify the best combinations?
    • Using immunology as a guide?
    • Combinations of any active compound?
  • What are the major mechanisms we need to focus on?
  • How successful have targeted combinations been so far?
    • IO-IO/ IO-Non-IO combos / Targeting the TME / Angiogenesis inhibitors / Standard of care agents
  • What are the best biomarkers for combination studies?
  • What major challenges remain?
Sep 2909:40
Conference pass
Sep 2909:40
Conference pass

Zika & Dengue vaccine update

Emerging and Infectious
Sep 2909:40
Conference pass

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

Bioprocess & Manufacture
  • Why and where will it make a difference?
  • How is it different to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like SARS-CoV-2? Can the scale-up/volume be big enough?
  • Does the speed and dosage have an effect on the overall quality of the vaccine?
Sep 2909:40
Conference pass

Successful strategies to mitigate risk in your supply chain and achieve your goals for your clinical programs

Supply & Logistics
Sep 2909:55
Conference pass

Innovating health care by accelerating life science start-ups through strategic advice and financing

Partnerships
Sep 2910:10
Conference pass

Characterizing differences in immune responses of different age populations and using this information to build next generation vaccines

Immune Profiling
Albert Shaw, Professor Of Medicine (Infectious Diseases), Yale University
Sep 2910:10
Conference pass

An update on RSV & Universal influenza vaccine development: Diversity matters

Respiratory
Barney Graham, Deputy Director Of Vaccine Research Center, National Institute of Health - NIAID
Sep 2910:10
Conference pass

Janssen’s Zika vaccine developments and new data

Emerging and Infectious
Dr Jenny Hendriks, Head Biomarkers, Janssen Vaccines & Prevention B.V.
Sep 2910:10
Conference pass

Preparedness for Coronavirus clinical trials

Clinical Development
Lynlee Burton, Senior Director Of Therapeutic Expertise - Vaccines, PRA Health Sciences
Sep 2910:10
Conference pass

Zoetis’ bench to market experience: Monoclonal antibodies for companion animals

Veterinary
Sep 2910:10
Conference pass

Does digital media provide any meaningful value for informing vaccine safety?

Vaccine Safety
Sep 2911:40
Conference pass

Omics studies in vaccine trials to deduce markers & mechanisms of protection for effective immunity

Immune Profiling
  • Analysis of differences in response between resource rich and resource poor areas; what can we learn from this?
Patrick Duffy, Chief Of Pathogenesis And Immunity Section, National Institutes of Health
Sep 2911:40
Conference pass

Advances in the determination and prioritization of neoantigens for the development of neoantigen-specific cancer vaccines

Cancer & Immunotherapy
Sep 2911:40
Conference pass

Results from the Ph2 trial of BPZE1 intranasal pertussis vaccine in healthy adults - Assessing immunity and safety using a prime or prime+boost schedule

Respiratory
Dr Cheryl Keech, Chief Medical Officer And Executive Vice President Of Clinical Research, ILiAD Biotechnologies, LLC
Karen Mccarthy, Executive Director, Vaccines, PPD
Sep 2911:40
Conference pass

New trial data from Malaria

Emerging and Infectious
Sep 2911:40
Conference pass

Why are seasonal, epidemic influenza vaccines losing efficacy?

Clinical Development
Sep 2911:40
Conference pass

Bioprocessing Adenovirus Associated Virus (AAV) – technical and economic considerations

Bioprocess & Manufacture
Sep 2911:40
Conference pass

Precision medicine for companion animals and humans: Vaccine-primed adoptive cell therapy targeting the patient’s specific cancer

Veterinary
Sep 2911:40
Conference pass

Showcase 1 - A synthetic carbohydrate-based conjugate vaccine against Shigella

Partnerships
Sep 2911:40
Conference pass

Joint presentation: Improving the ways that we engage with individuals around immunization: development and implementation of new and existing tools

Vaccine Safety
·Should we be using a single vs. bundle approach to improve vaccine uptake? Or are we missing the point when it comes to improving coverage?(25min) Dr Holly Seale·Effective communication for promoting immunization uptake(25min) Professor John Parrish-Sprowl·Q&A (10 min)
Sep 2911:55
Conference pass

Accelerating Development, Lowering Costs and Improving The Performance Of Recombinant Vaccines, Antigens & Vlp's

Bioprocess & Manufacture
Sep 2911:55
Conference pass

Showcase 2 - Toxoid Vaccine against Epsilon Toxin – the Trigger for both Enterotoxaemia and Multiple Sclerosis?

Partnerships
Sep 2912:10
Conference pass

Immunosenescence and influenza vaccination in older individuals

Immune Profiling
Sep 2912:10
Conference pass

Development of oncolytic virus therapies using an HSV platform

Cancer & Immunotherapy
John Goldberg, Senior Vice President Of Clinical Development, Oncorus
Sep 2912:10
Conference pass

Novel insights in RSV transmission from animal models

Respiratory
Dr Koert Stittelaar, General Manager Viroclinics Xplore, Viroclinics Biosciences B.V.
Sep 2912:10
Conference pass

AV7909 Next-generation Anthrax vaccine: Progress towards licensure

Emerging and Infectious
Josh Reece, Director Of Product Development, Emergent Biosolutions
Sep 2912:10
Conference pass
Sep 2912:10
Conference pass

CanSino’s adenovirus-based viral vector technology platform and its applications in vaccine development

Bioprocess & Manufacture
Helen Huihua Mao, Senior Vice President, CanSino Biologics Inc.
Sep 2912:10
Conference pass

Novel industrially proven hyper productive C1 expression system for biotherapeutics such as vaccines & antibodies

Veterinary
Sep 2912:10
Conference pass

Showcase 3 - Creation of universal viral vectors for development of vaccines against emerging infectious diseases; Foundation for our newly developed MERS-CoV and Zika virus vaccines

Partnerships
Sep 2912:10
Conference pass

Can we achieve global harmonization of regulatory requirements for vaccines

Supply & Logistics
  • Managing regulatory requirements and timelines while rolling out vaccine globally
  • Variability of assays and tests required internationally
  • Practicalities are very challenging – how do big pharma manage this?
  • Insurance of process control – what will satisfy regulatory bodies downstream?
  • When and how should you engage with regulatory bodies
Sep 2912:25
Conference pass

Large animal challenge models for assessment of human and veterinary negative strand virus recombinant vaccines

Veterinary
Louise Cosby, Head Of Virology, Agri-Food and Biosciences Institute
Sep 2912:25
Conference pass

Showcase 4 - Safety study of the first in human phase I trial with a novel RSV recombinant G protein-based vaccine

Partnerships
Sep 2912:40
Conference pass

Immune profiling and biomarker-based approaches during clinical development of novel vaccines: Are we there yet?

Immune Profiling
Rolando Pajon, Director, Moderna Inc.
Sep 2912:40
Conference pass

Autologous dendritic cell vaccines show promise against prostate and HER2-expressing cancers

Cancer & Immunotherapy
Sep 2912:40
Conference pass

Clinical outcome of the development of an 60—75 year old RSV challenge model for the evaluation of vaccines

Respiratory
Sep 2912:40
Conference pass

Recombinant nanoparticle COVID-19 vaccine: Platform technology for EID

Emerging and Infectious
Gregory Glenn, President, Research And Development, Novavax
Sep 2912:40
Conference pass

Accelerating vaccine process development and increasing productivity - Downstream Processing

Bioprocess & Manufacture
Sep 2912:40
Conference pass

Novel vaccine technique to target multiple poultry diseases using CRISPR/Cas9 system

Veterinary
Venugopal Nair, Head, The Pirbright Institute
Sep 2912:40
Conference pass

Showcase 5 - A Messenger RNA (mRNA) Vaccine Against Cytomegalovirus (CMV) Infection: Phase 1 Interim Data

Partnerships
Sep 2912:40
Conference pass

Public perceptions of vaccines; a media perspective

Vaccine Safety
Sep 2912:55
Conference pass

Showcase 6 - Evaluation of Combined Shigella-ETEC vaccine Candidates in the Human Enteroid Model

Partnerships
Sep 2914:40
Conference pass

The potential use of human in vitro models to help build better vaccines

Immune Profiling
David Dowling, Instructor In Pediatrics, Boston Children's Hospital
Sep 2914:40
Conference pass

A powerful phage-based immunotherapy platform for enhanced immune system activation

Cancer & Immunotherapy
Robert Pierce, CSO, Sensei Bio
Sep 2914:40
Conference pass

Actionable Insights Gained from Evaluating Universal Influenza Vaccine Strategies in Healthy Volunteer Challenge Studies

Respiratory
Sep 2914:40
Conference pass

Using GV-MVA-VLP™ technology to advance a COVID-19 vaccine candidate towards testing, in collaboration with Chinese biotech BravoVax

Emerging and Infectious
Dr Farshad Guirakhoo, Chief Scientific Officer, GeoVax, Inc.
Sep 2914:40
Conference pass

The advantages of conducting early phase clinical trials in Australia

Clinical Development
Angela Luttick, EVP, Business Development, 360biolabs Pty Ltd
Max Rossetto, General Manager Business Development, Luina Bio
Sep 2914:40
Conference pass

Increasing production of live viral vaccines and vectors with novel bioreactor technologies

Bioprocess & Manufacture
  • A historical perspective on adherent and non-adherent live-virus vaccine production and how recent advances in bioreactors allow for greater productivity and reduced costs per dose
Eric Vela, Associate Director Of Upstream Development, Ology Bioservices, Inc.
Sep 2914:40
Conference pass

Development of a highly effective African swine fever virus vaccine by deletion of the I177L gene

Veterinary
Douglas Gladue, Senior Scientist, Plum Island Animal Disease Center, USDA
Sep 2914:40
Conference pass

Success case study 1 - How a network of research centers work together in a multidisciplinary effort to develop better influenza vaccines

Partnerships
Sep 2914:40
Conference pass

Panel: Unravelling dengue vaccine safety concerns: To what extend could they have been predicted?

Vaccine Safety
  • Use of controlled human infection models
  • Need for complete assessment of viremia induced by the vaccine
  • The importance of balanced infectivity in live attenuated vaccines and balanced efficacy across age groups and sero-status
  • Surveillance:
    • Need for improved surveillance systems where dengue vaccine is introduced
    • How long should active surveillance continue?
    • Collection of blood samples – baseline & routinely scheduled collections
Sep 2914:55
Conference pass

Generation and development of a vaccine against Nipah virus

Emerging and Infectious
Ultan Power, Professor Of Molecular Virology, Wellcome Wolfson Institute For Experimental Medicine, Queen's University Belfast
Sep 2914:55
Conference pass

Success case study 2 - Partnering with a non-profit for the first toxoid based multivalent vaccine for MRSA

Partnerships
M Javad Aman, Chief Executive Officer, Integrated Biotherapeutics
Sep 2915:10
Conference pass

Interactive Discussion: How can we use data to inform next generation vaccines?

Immune Profiling
  • Exploring immune profiling platforms to accelerate and de-risk vaccine development
  • Can modelling immune responses outside the body human help to do this?
  • How can we use big data to inform next generation vaccines?
Sep 2915:10
Conference pass

Efficacy, safety, and immunogenicity of a plant-derived, quadrivalent, virus-like particle influenza vaccine in younger (18-64 years of age) and older (≥65 years of age) adults

Respiratory
Sep 2915:10
Conference pass

Successful Project Delivery through Laboratory and Clinical Integration

Clinical Development
Sep 2915:10
Conference pass

Proving vaccine availability for Global Health: Establishing a resource of manufacturing know-how & materials

Bioprocess & Manufacture
Chris Yallop, Chief Operations And Scientific Officer, Batavia Biosciences
Sep 2915:10
Conference pass

Current status of rift valley fever vaccine development

Veterinary
  • Challenges and strategies for developing efficacious rift valley fever vaccines
John Wyckoff, Director, Colorado State University
Sep 2915:10
Conference pass

Leveraging multidisciplinary alliances for threat detection and ultra-rapid development & deployment of pharmaceutical countermeasures for catastrophic, unanticipated and point-of-use medical needs

Supply & Logistics
Sep 2915:25
Conference pass

Cancer vaccine delivery by precise intradermal administration

Cancer & Immunotherapy
Sep 2915:25
Conference pass

Advancements towards the first commercial Chikungunya vaccine and repurposing the platform for COVID-19

Emerging and Infectious
Dr Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience
Sep 2915:40
Conference pass

Single cell functionality serves as a predictive biomarker for overall survival of pancreatic cancer patients treated with GVAX vaccine

Immune Profiling
Dr Will Singleterry, Director Of Business Development, IsoPlexis
Sep 2915:40
Conference pass

Designing tumor specific neoantigen-targeted personalized immunotherapies against cancer

Cancer & Immunotherapy
Dr Niranjan Sardesai, President And Chief Executive Officer, Geneos Therapeutics
Sep 2915:40
Conference pass

Impact of pre-existing immunity on the outcome of vector-based vaccine and gene therapy clinical trials: Evolution of delivery-vector viral neutralization assays

Clinical Development
Sep 2915:40
Conference pass

Title TBC

Bioprocess & Manufacture
Richard Welch, Vice President Of Process Of Analytical Development, Emergent Biosolutions
Sep 2915:40
Conference pass

Emerging trends in veterinary vaccine delivery systems

Veterinary
Arvind Kumar, Lead, Discovery Biology Research (Bacteriology And Parasitology) Erl, Elanco Animal Health
Sep 2915:40
Conference pass

Low side-effect safety profile demonstrated in phase 1 trial of shingles vaccine candidate CRV-101

Vaccine Safety
Lisa Shelton, Associate Director Of Operations, Curevo Vaccine
Sep 2915:55
Conference pass

Sci-B-Vac: results on Ph3 Hep B vaccine

Emerging and Infectious
Dr Francisco Diaz-Mitoma, Chief Medical Officer, VBI Vaccines
Sep 2915:55
Conference pass

Clinical development: site’s perspective on frequent issues around vaccine trials

Clinical Development
William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC
Sep 2916:35
Conference pass

Chair’s opening remarks

Bioprocess & Manufacture
Sep 2916:40
Conference pass

Unbiased functional analysis of cell-mediated immunity in healthy volunteers receiving a quadrivalent seasonal VLP vaccine

Immune Profiling
Scott Sugden, Senior Principal Scientist, Caprion Biosciences
Sep 2916:40
Conference pass

Flugen’s universal flu vaccine development

Respiratory
Joseph Eiden, Senior Medical Advisor, FluGen Inc
Sep 2916:40
Conference pass

A novel vaccine for monkeypox – current status and outlook

Emerging and Infectious
Sep 2916:40
Conference pass

Transforming the peripheral blood clinical sample supply chain with a simple, automated solution

Clinical Development
Sep 2916:40
Conference pass

Considerations for the process development and cGMP manufacturing of vaccines

Bioprocess & Manufacture
Sep 2916:40
Conference pass

Overcoming manufacturing challenges in the veterinary vaccine industry

Veterinary
  • Designing and commissioning high throughput manufacturing facilities
  • Facility and equipment design suitable for campaign production
  • Use of appropriate disposable technologies
  • Improving antigen yield through process optimization
Sep 2916:40
Conference pass

Investing on late stage projects to contribute towards global health

Partnerships
Sep 2916:40
Conference pass

Post-marketing assessment of vaccine safety in pregnancy

Vaccine Safety
  • Key issues surrounding post-marketing safety surveillance for vaccines used during pregnancy
  • Update on changes in recently published Post-approval Pregnancy Safety Studies
Sep 2916:55
Conference pass

Using systems serology to identify humoral correlates of protection following malaria vaccination

Immune Profiling
  • New correlate and challenge data from Janssen’s Malaria vaccine
Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Vaccines & Prevention B.V.
Todd Suscovich, Chief Technical Officer, Seromyx
Sep 2916:55
Conference pass

Modernization of the influenza vaccine

Bioprocess & Manufacture
Daniel Henderson, Chief Executive Officer, Verndari
Sep 2917:10
Conference pass

Vaccitech update – New data for a universal vaccine

Respiratory
Thomas Evans, Chief Executive Officer, Vaccitech
Sep 2917:10
Conference pass

Expeditionary research in emerging & re-emerging disease – session title TBC

Emerging and Infectious
Sep 2917:10
Conference pass

Willingness to participate in vaccine-related clinical trials among older adults

Clinical Development
Nadine Rouphael, Associate Professor Of Medicine, Emory University
Sep 2917:10
Conference pass

Alternative delivery system technology showcase

Bioprocess & Manufacture
Sep 2917:10
Conference pass

Advances in AntiRabies Vaccine (ARV) Technology

Veterinary
Sep 2917:10
Conference pass
Sep 2917:10
Conference pass

Vaccine safety surveillance: what can we do to improve surveillance studies and databases?

Vaccine Safety
  • What are the benefits of RCTs and large databases and how can they be improved?
    • How might it be enhanced?
  • How do we decide which signals are meaningful?
    • What is the existing infrastructure to evaluate signals
    • What processes are being added to speedup signal detection?
  • The need for better databases in LMICs – how do you recognize safety signals? How can they be implemented?
    • What international efforts are ongoing?
    • What is pharma doing to enhance pharmocovigilance
  • Evaluating vaccine safety in pregnant women and other at-risk populations
    • How can safety be monitored effectively in pregnant women and their offspring?
    • Emphasis on ways to increase the availability of vaccines for pregnant women
Sep 2917:10
Conference pass

Novel technology to monitor product quality in vaccine supply chains

Supply & Logistics
Souleymane Sawadogo, General Manager, Global Health, Parsyl
Sep 2917:25
Conference pass

Proteomic contributions to our understanding of vaccine and immune responses

Immune Profiling
Sep 2917:25
Conference pass

Alternative delivery system technology showcase: High volume, aseptic manufacturing of microneedle products

Bioprocess & Manufacture
Sep 2917:25
Conference pass

Panel: How do you meet the demand of low-cost manufacturing using new vaccine modalities?

Veterinary
Volker Gerdts, Director And Chief Executive Officer, VIDO-InterVac
Dr Jean-Christophe Audonnet, Senior Director, International R&D Governance, Coordinator Of Zapi Imi Project, Merial
Sep 2917:40
Conference pass

Developing high throughput experimental and analytical tools to evaluate the antibody response in infectious disease

Immune Profiling
Margaret Ellen Ackerman, Associate Engineering Professor, Dartmouth College
Sep 2917:40
Conference pass

How vaccine delivery solutions impact the efficiency of vaccine campaigns

Respiratory
Sep 2917:40
Conference pass

Current State of CMV Vaccine Development

Emerging and Infectious
Stanley Plotkin, Emeritus Professor, University of Pennsylvania School Of Medicine
Sep 2917:40
Conference pass

Strategy for conducting international vaccine clinical trials for infants and toddlers

Clinical Development
  • Using insight/data from pneumococcal and meningococcal A vaccines
Mark Alderson, Director - Pneumococcal Vaccine Project Vaccine Development Global Program, Path
Sep 2917:40
Conference pass

Overcoming cold chain challenges using drone delivery

Supply & Logistics
Sep 2917:55
Conference pass

How do different routes of delivery influence the immunological outcome?

Bioprocess & Manufacture
  • Effectiveness and usability
last published: 24/Mar/20 14:25 GMT